Hengrui Medicine (600276.SH): SHR-1139 injection clinical trial approved Currently, there are no similar drugs approved for marketing at home and abroad.

Intelligence Finance APP News, Hengrui Medicine (600276.SH) announced that its subsidiary Guangdong Hengrui Medicine Co., Ltd. recently received the "Drug Clinical Trial Approval Notification" issued by the National Medical Products Administration for SHR-1139 injection, and will soon conduct clinical trials. SHR-1139 injection is a therapeutic biological product independently developed by the company. According to the inquiry, there are currently no similar drugs approved for market in China or abroad. As of now, the accumulated research and development investment for the SHR-1139 injection project is approximately 100.13 million yuan.